Finance entity

Bachem

Company BCHMF

earnings is the sole category represented across all 1 tracked stories. Bachem is most often covered alongside Codexis, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.

Last mentioned: Mar 24, 2026

Entity pulse

Recent coverage · Bachem

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Bachem

earnings is the sole category represented across all 1 tracked stories. Bachem is most often covered alongside Codexis, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Finance story that mention Bachem, all published on March 24, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 119 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Bachem. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Sentiment Review

    Major analysts maintain existing price targets and ratings despite the earnings beat.

  2. Analyst Upgrade

    Wall Street Zen upgrades CDXS rating following financial results.

  3. Q4 2025 Earnings

    Codexis reports surprise profit and revenue beat.

  4. TD Cowen Conference

    CEO touts ECO Synthesis push and 2026 inflection targets.

Stories mentioning Bachem 1

Earnings Neutral

Codexis Holds Steady as ECO Synthesis Gains Traction Post-Q4 Earnings Beat

Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.

2 sources

Bachem is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.